Practical management of patients on apixaban: a consensus guide

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Atrial fibrillation (AF) is a prevalent arrhythmia in Australia, increasing stroke risk.
• Stroke prevention is crucial in AF management, with novel oral anticoagulants (NOACs) like apixaban now available.
• Apixaban, a factor Xa inhibitor, has demonstrated superiority over warfarin in preventing stroke and systemic embolism in non-valvular AF (NVAF) patients.

Purpose of the Study:

• To provide a consensus-based guide for Australian healthcare practitioners prescribing apixaban for stroke prevention in NVAF.
• To focus on the acute and emergency management of patients taking apixaban.
• To address the limited clinical experience and evidence regarding bleeding and invasive procedures in patients on apixaban.

Main Methods:

• Summarization of available animal and ex vivo human data.
• Multi-disciplinary consensus development.
• Literature review of clinical trial data and pharmacokinetic properties.

Main Results:

• Apixaban is superior to warfarin in preventing stroke and systemic embolism in NVAF patients.
• Apixaban use was associated with reduced bleeding and mortality rates compared to warfarin in clinical trials.
• Predictable pharmacokinetics and minimal drug interactions support safe anticoagulation with apixaban.

Conclusions:

• Apixaban offers safe anticoagulation for most patients, allowing temporary interruption for procedures.
• Standard supportive treatment is recommended for actively bleeding patients on apixaban in the absence of specific data.
• Quantitative assays for apixaban levels are emerging, but their clinical utility and specific antidotes are still under development.